The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
Pembrolizumab Combo Fails in Melanoma
April 6th 2018The combination of the PD-1 inhibitor pembrolizumab and the IDO1 inhibitor epacadostat failed to improve progression-free survival versus single-agent pembrolizumab in patients with unresectable or metastatic melanoma, according to findings from the phase III ECHO-301/KEYNOTE-252 trial.
EMA to Review Olaparib in BRCA-mutated, HER2-negative Breast Cancer
April 3rd 2018The European Medicines Agency has accepted a marketing authorization application for olaparib to treat women with BRCA-mutated, HER2-negative metastatic breast cancer who previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.
Novel Radiolabeled ADC Could Improve Outcomes in High-Risk AML
April 2nd 2018Older patients with active, relapsed, or refractory acute myeloid leukemia have a low survival rate, very poor risk assessments, and limited therapeutic options, with conventional care consisting primarily of salvage chemotherapy.
Nivolumab Delivers Durable Response in Hodgkin Lymphoma at 18 Months
April 2nd 2018In an extended follow-up of results from the CheckMate-205 trial, nivolumab (Opdivo) induced an overall objective response rate of 69% in patients with relapsed/refractory classical Hodgkin lymphoma after autologous hematopoietic cell transplantation.